The natriuretic peptides in cardiovascular medicine

被引：126

作者：

Munagala, VK ^{[1
]}

Burnett, JC ^{[1
]}

Redfield, MM ^{[1
]}

机构：

[1] Mayo Clin, Rochester, MN 55905 USA

来源：

CURRENT PROBLEMS IN CARDIOLOGY | 2004年 / 29卷 / 12期

关键词：

D O I：

10.1016/j.cpcardiol.2004.07.002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Within the last five years, assay systems for measurement of plasma levels of brain natriuretic peptide (BNP) have been approved as a diagnostic aid for heart failure (HF). Similarly, nesiritide, a recombinant form of human BNP, has been approved for the treatment of acutely decompensated HE Both BNP as a diagnostic test and a therapeutic modality are rapidly becoming integrated into clinical practice. The purpose of this review is to provide a brief overview of the physiology of the natriuretic peptides relevant to their informed clinical use. The current literature regarding the utility of measuring BNP for the diagnosis and management of HF is reviewed and practical recommendations regarding the interpretation of BNP levels are offered. The clinical literature regarding the use of recombinant BNP for the treatment of HF is reviewed, underscoring current gaps in our knowledge regarding the indications for and benefits of this novel agent.

引用

页码：707 / 769

页数：63

共 158 条

[1] Abraham W T, 1998, J Card Fail, V4, P37, DOI 10.1016/S1071-9164(98)90506-1
[2] Prognostic value of Doppler transmitral flow patterns and cardiac natriuretic peptides in patients with chronic congestive heart failure admitted for episodes of acute decompensation
Akioka, K
Takeuchi, K
Yanagi, S
Hirota, K
Sakamoto, K
Yoshimura, T
Toda, I
Yoshikawa, J
[J]. HEART AND VESSELS, 2000, 15 (02) : 53 - 60
[3] Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)
Anand, IS
Fisher, LD
Chiang, YT
Latini, R
Masson, S
Maggioni, AP
Glazer, RD
Tognoni, G
Cohn, JN
[J]. CIRCULATION, 2003, 107 (09) : 1278 - 1283
[4] Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction
Arakawa, N
Nakamura, M
Aoki, H
Hiramori, K
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 27 (07) : 1656 - 1661
[5] Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction - Japan-Working groups of acute myocardial infarction for the reduction of necrotic damage by ANP (J-WIND-ANP)
Asakura, M
Jiyoong, K
Minamino, T
Shintani, Y
Asanuma, H
Kitakaze, M
[J]. CIRCULATION JOURNAL, 2004, 68 (02) : 95 - 100
[6] Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale
Bando, M
Ishii, Y
Sugiyama, Y
Kitamura, S
[J]. RESPIRATORY MEDICINE, 1999, 93 (07) : 507 - 514
[7] HEMODYNAMICS IN TRANSGENIC MICE WITH OVEREXPRESSION OF ATRIAL-NATRIURETIC-FACTOR
BARBEE, RW
PERRY, BD
RE, RN
MURGO, JP
FIELD, LJ
[J]. CIRCULATION RESEARCH, 1994, 74 (04) : 747 - 751
[8] Evaluation of brain natriuretic peptide in the diagnosis of heart failure
Bettencourt, P
Ferreira, A
Dias, P
Castro, A
Martins, L
Cerqueira-Gomes, M
[J]. CARDIOLOGY, 2000, 93 (1-2) : 19 - 25
[9] RULING OUT OR RULING IN DISEASE WITH THE MOST SENSITIVE OR SPECIFIC DIAGNOSTIC-TEST - SHORT-CUT OR WRONG TURN
BOYKO, EJ
[J]. MEDICAL DECISION MAKING, 1994, 14 (02) : 175 - 179
[10] Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects
Brunner-La Rocca, HP
Kaye, DM
Woods, RL
Hastings, J
Esler, MD
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (05) : 1221 - 1227

← 1 2 3 4 5 6 7 8 9 10 →